These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30244431)

  • 1. International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
    Jansen TL; Perez-Ruiz F; Tausche AK; Richette P
    Clin Rheumatol; 2018 Dec; 37(12):3159-3165. PubMed ID: 30244431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
    Cicero AFG; Fogacci F; Kuwabara M; Borghi C
    Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33435164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
    Lee MH; Graham GG; Williams KM; Day RO
    Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lesinurad: First Global Approval.
    Hoy SM
    Drugs; 2016 Mar; 76(4):509-16. PubMed ID: 26861027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lesinurad for the treatment of hyperuricaemia in people with gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2017 Dec; 18(17):1875-1881. PubMed ID: 29103339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New urate-lowing therapies.
    Abhishek A
    Curr Opin Rheumatol; 2018 Mar; 30(2):177-182. PubMed ID: 29251661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lesinurad (Zurampic) for gout-associated hyperuricemia.
    Med Lett Drugs Ther; 2016 Nov; 58(1508):148-150. PubMed ID: 27849193
    [No Abstract]   [Full Text] [Related]  

  • 10. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
    Jones G; Panova E; Day R
    Drug Des Devel Ther; 2017; 11():3077-3081. PubMed ID: 29123379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
    Kydd AS; Seth R; Buchbinder R; Falzon L; Edwards CJ; van der Heijde DM; Bombardier C
    J Rheumatol Suppl; 2014 Sep; 92():33-41. PubMed ID: 25180126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New medications in development for the treatment of hyperuricemia of gout.
    Diaz-Torné C; Perez-Herrero N; Perez-Ruiz F
    Curr Opin Rheumatol; 2015 Mar; 27(2):164-9. PubMed ID: 25603039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Fung M; Baumgartner S; Perez-Ruiz F
    Arthritis Res Ther; 2019 Jan; 21(1):8. PubMed ID: 30616614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapies for gout.
    Edwards NL; So A
    Rheum Dis Clin North Am; 2014 May; 40(2):375-87. PubMed ID: 24703353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
    Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational pharmacotherapy (RPT) in goutology: Define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs.
    Jansen TL
    Joint Bone Spine; 2015 Jul; 82(4):225-9. PubMed ID: 26113027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
    Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
    Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
    Presa M; Pérez-Ruiz F; Oyagüez I
    Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.